Market Overview - The chemical pharmaceutical sector increased by 0.16% on December 1, with Changshan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Top Gainers in Chemical Pharmaceutical Sector - Changshan Pharmaceutical (300255) closed at 67.70, up 8.93% with a trading volume of 353,700 shares and a transaction value of 2.379 billion [1] - Laimei Pharmaceutical (300006) closed at 5.42, up 5.24% with a trading volume of 821,100 shares [1] - Oukang Pharmaceutical (920230) closed at 13.22, up 3.44% with a trading volume of 11,400 shares [1] Top Losers in Chemical Pharmaceutical Sector - Yifang Bio (688382) closed at 27.05, down 8.24% with a trading volume of 315,300 shares [2] - Keyuan Pharmaceutical (301281) closed at 27.96, down 4.51% with a trading volume of 44,300 shares [2] - Kangzhiyue Pharmaceutical (300086) closed at 12.17, down 4.32% with a trading volume of 864,700 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 1.011 billion from institutional investors, while retail investors saw a net inflow of 466 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Maiwei Bio (688062) had a net inflow of 48.528 million from institutional investors, but a net outflow of 65.659 million from retail investors [3] - Lijun Group (000513) saw a net inflow of 23.529 million from institutional investors, with a net outflow of 25.007 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 18.642 million from institutional investors, while retail investors experienced a net inflow of 10.459 million [3]

证券日报网讯11月27日晚间，莱美药业（300006）发布公告称，近日，重庆莱美药业股份有限公司(以 下简称"公司")收到国家药品监督管理局核准签发的注射用氨曲南(规格：0.5g)《药品补充申请批准通知 书》。 ...

Core Viewpoint - Lai Mei Pharmaceutical has received approval from the National Medical Products Administration for the injection of Aztreonam (0.5g), which is indicated for the treatment of infections caused by sensitive Gram-negative bacteria [1] Group 1 - The approved drug, Aztreonam, is suitable for treating various infections, including urinary tract infections (both uncomplicated and complicated), lower respiratory tract infections, sepsis, skin and skin structure infections, intra-abdominal infections, and gynecological infections [1]

证券代码：300006 证券简称：莱美药业 公告编号：2025-056 | 药品名称 | 通用名称：注射用氨曲南 | | --- | --- | | | 英文名/拉丁名：Aztreonam for Injection | | 剂型 | 注射剂 | | 注册分类 | 化学药品 | | 规格 | 0.5g | | 包装规格 | 瓶/盒 10 | | 通知书编号 | 2025B05696 | | 原药品批准文号 | 国药准字 H20059939 | | 药品注册标准编号 | YBH31162025 | | 申请内容 | 申请注射剂仿制药质量和疗效一致性评价，其他变更事项包括：1.变更 | | | 药品质量标准（包括有效期和贮藏条件）；2.变更直接接触药品的包装 | | | 材料和容器。 根据《中华人民共和国药品管理法》《国务院关于改革药品医疗器械审 | | | 评审批制度的意见》（国发〔2015〕44 号）《关于仿制药质量和疗效一 | | | 致性评价工作有关事项的公告》（2017 年第 100 号）和《国家药监局关 | | | 于开展化学药品注射剂仿制药质量和疗效一致性评价工作的公告》 | | 审批结论 | （2 ...

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for the injectable Amikacin (specification: 0.5g), which has passed the consistency evaluation for generic injectable drugs and includes changes to quality standards and packaging materials [1] Group 1 - The injectable Amikacin is indicated for the treatment of various infections, with 12 manufacturers having passed the consistency evaluation to date [1] - The sales revenue for injectable Amikacin in the Chinese hospital market is projected to be 259 million yuan, 220 million yuan, and 40 million yuan for the years 2023, 2024, and the first half of 2025, respectively [1] - The approval is expected to facilitate market expansion for the product, although there are uncertainties regarding production and sales [1]

Core Viewpoint - Lai Mei Pharmaceutical has received approval from the National Medical Products Administration for the injection of Aztreonam (0.5g), which is indicated for the treatment of infections caused by sensitive Gram-negative bacteria [1] Group 1 - The approved drug, Aztreonam, is suitable for treating various infections, including urinary tract infections (both uncomplicated and complicated), lower respiratory tract infections, sepsis, skin and skin structure infections, intra-abdominal infections, and gynecological infections [1]

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

证券日报网讯莱美药业（300006）11月25日在互动平台回答投资者提问时表示，截至2025年11月20日， 公司股东户数为30，614户。 ...

Group 1 - The number of shareholders for Laimei Pharmaceutical as of November 20 is 30,614, a decrease of 4,399 from the previous period (November 10), representing a decline of 12.56%. This marks the third consecutive period of decline in shareholder numbers [2] - As of the latest closing price, Laimei Pharmaceutical's stock price is 5.01 yuan, reflecting an increase of 2.04%. Since the concentration of shares began, the stock price has cumulatively risen by 0.80%, with 5 days of increases and 6 days of decreases [2] - The latest margin trading data shows that as of November 24, the total margin balance for the stock is 200 million yuan, with a financing balance of 200 million yuan. During the current concentration period, the financing balance has decreased by 6.0383 million yuan, a decline of 2.93% [2] Group 2 - According to the company's third-quarter report, Laimei Pharmaceutical achieved a total operating revenue of 581 million yuan in the first three quarters, a year-on-year decrease of 4.06%. The net profit for the same period is -45.9172 million yuan, a year-on-year decline of 73.82%, with basic earnings per share at -0.0435 yuan [2]

证券日报网讯莱美药业（300006）11月19日在互动平台回答投资者提问时表示，公司持续推进产品引进 工作，并获取了部分药械相关品种销售代理权。后续公司将进一步优化产品结构，加快产品与技术引 进，推动相关品种市场拓展。 ...